Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Keywords hepatocellular carcinoma CRISPR screening STK40 anti-tumor immunity immunotherapy Get full text access Log in, subscribe or purchase for full access. References 1. Llovet, J.M. ∙ Castet, F. ∙ Heikenwalder, M. ... Immunotherapies for hepatocellular carcinoma Nat. Rev. Clin. Oncol. 2022; 19:151-172 2. Sangro, B. ∙ Sarobe, P. ∙ Hervás-Stubbs, S. ... Advances in immunotherapy for hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. 2021; 18:525-543 3. Wang, Z. ∙ Wang, Y. ∙ Gao, P. ...
1State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute & Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2Immune Regulation in Cancer Group, German Cancer Research Center (DKFZ), Heidelberg, Germany 3Department of Liver Surgery and Transplantation, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Medical...
Abstract Ferroptosis is a unique form of intracellular iron-dependent cell death that differs from apoptosis, necrosis, and autophagy. GPX4, an antioxidant defense enzyme, plays a pivotal role as regulator of ferroptosis. Extensive researches suggest that targeting GPX4 holds promise for cancer therapy. However, the current GPX4 inhibitors face challenges due to unfavorable drug-like properties, which hinder their progress in clinical development.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
